BioVid Launches Tumor Worlds™: A Strategic Intelligence System to Decode the Behavioral Logic of Oncology Markets
BRISTOL, Pa., Aug. 27, 2026 /PRNewswire/ -- BioVid, a leading life science consultancy, today announced the launch of Tumor Worlds™, a proprietary strategic intelligence system that helps pharmaceutical companies anticipate how oncology markets respond to new evidence. Integrating oncology expertise, behavioral science, and BioVid's proprietary CIAIRA™ AI platform, Tumor Worlds™ moves beyond descriptive market research to provide an early signal model of physician decision-making. The launch begins with Non-Small Cell Lung Cancer (NSCLC), with Prostate and Pancreatic Cancer to follow, and full portfolio expansion planned through 2026.
To learn more, visit www.biovid.com/tumorworlds.
Clinical evidence now moves faster than most markets can absorb, and one-size-fits-all launch playbooks weren't built for that pace. Tumor Worlds™ maps the "gravitational forces" of each oncology market, identifying the structural conditions that govern how new evidence is adopted in clinical practice.
"The industry is trapped in a 'rearview mirror' approach, relying on historical data to predict what physicians will do next," said Peggy Hirtle, CEO of BioVid. "We've mapped the sociotechnical forces — social norms, institutional constraints, cognitive heuristics — that drive physician behavior, so clients can anticipate where market change will accelerate, stall, or fail before it appears in prescription data."
"Success in oncology is no longer just about having the best data; it's about understanding the social and structural reality of the physician," said Meredith Jacobetz, PhD, Senior Director, Oncology Center of Excellence at BioVid. "Tumor Worlds™ lets us build an actionable picture of the world an asset inhabits before that reality shows up in the data."
Tumor Worlds™ includes four core suites, powered by a sociotechnical engine mapping behavioral rules across 30+ tumor types:
World Dynamics Suite: Maps the clinical and competitive landscape shaping how fast a market can move.
Treater Insights Suite: Maps physician roles and influence networks, from awareness to prescribing.
Cognitive Insights Suite: Surfaces the psychological drivers behind physician decisions and where messaging fails.
Lifecycle Intelligence Suite: Calibrates risk flags, competitive playbook, and resource allocation across an asset's life.
CIAIRA™: BioVid's proprietary AI engine synthesizes data across all four suites to identify leading indicators of physician sentiment as the market evolves.
About BioVid
BioVid is a life science consultancy applying behavioral science and AI to commercial and market access strategy, marrying market opportunity with behavioral insight for clients.
Visit www.biovid.com to learn more.
Media Contact:
Lynn Clement, Executive Director, Growth Strategy, BioVid
SOURCE BioVid
Share this article